ORIC PHARMACEUTICALS, INC. Proceeds from Issuance of Preferred Stock and Preference Stock
ORIC PHARMACEUTICALS, INC. (ORIC) reported Proceeds from Issuance of Preferred Stock and Preference Stock of $354.00 thousand for the 9-month period ending 2022-09-30, per its 10-Q filed 2022-11-07.
Discontinued › Cash Flow › Financing Activities
us-gaap:ProceedsFromIssuanceOfPreferredStockAndPreferenceStock · last filed 2022-11-07
- ORIC PHARMACEUTICALS, INC. proceeds from issuance of preferred stock and preference stock for the quarter ending 2021-12-31 was $0.00.
- ORIC PHARMACEUTICALS, INC. proceeds from issuance of preferred stock and preference stock for the quarter ending 2019-12-31 was -$135.00K.
- ORIC PHARMACEUTICALS, INC. proceeds from issuance of preferred stock and preference stock for the quarter ending 2019-09-30 was $5.80M.
- ORIC PHARMACEUTICALS, INC. proceeds from issuance of preferred stock and preference stock for the quarter ending 2019-06-30 was $49.86M.
- ORIC PHARMACEUTICALS, INC. proceeds from issuance of preferred stock and preference stock for fiscal 2021 was $0.00.
- ORIC PHARMACEUTICALS, INC. proceeds from issuance of preferred stock and preference stock for fiscal 2020 was $0.00, a 100.00% decline from fiscal 2019.
- ORIC PHARMACEUTICALS, INC. proceeds from issuance of preferred stock and preference stock for fiscal 2019 was $70.79M, a 86.64% increase from fiscal 2018.
- ORIC PHARMACEUTICALS, INC. proceeds from issuance of preferred stock and preference stock for fiscal 2018 was $37.93M.
| Period end | Proceeds from Issuance of Preferred Stock and Preference Stock 3 month | Proceeds from Issuance of Preferred Stock and Preference Stock 6 month | Proceeds from Issuance of Preferred Stock and Preference Stock 9 month | Proceeds from Issuance of Preferred Stock and Preference Stock 12 month |
|---|---|---|---|---|
| 2022-09-30 | $354.00K 10-Q · filed 2022-11-07 | |||
| 2021-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-21 | $0.00 10-K · filed 2022-03-21 | ||
| 2021-09-30 | $0.00 10-Q · filed 2022-11-07 | |||
| 2020-12-31 | $0.00 10-K · filed 2022-03-21 | |||
| 2019-12-31 | -$135.00K derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-21 | $5.67M derived: sum of 2 quarters · filed 2022-03-21 | $55.53M derived: sum of 3 quarters · filed 2022-03-21 | $70.79M 10-K · filed 2022-03-21 |
| 2019-09-30 | $5.80M derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-05 | $55.67M derived: sum of 2 quarters · filed 2020-11-05 | $70.93M 10-Q · filed 2020-11-05 | |
| 2019-06-30 | $49.86M derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-05 | $65.12M 10-Q · filed 2020-08-05 | ||
| 2019-03-31 | $15.26M 10-Q · filed 2020-05-20 | |||
| 2018-12-31 | $37.93M 10-K · filed 2021-03-23 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Kardigan, Inc. (KARD) | United States | $1.346B | |
| Tyra Biosciences, Inc. (TYRA) | United States | $1.337B | -12.83 |
| Bicara Therapeutics Inc. (BCAX) | United States | $1.309B | -10.55 |
| First Tracks Biotherapeutics, Inc. (TRAX) | United States | $1.280B | |
| OMEROS CORP (OMER) | United States | $1.456B | 5.50 |
| Ultragenyx Pharmaceutical Inc. (RARE) | United States | $1.456B | -5.62 |
| Avalyn Pharma Inc. (AVLN) | United States | $1.267B | |
| Damora Therapeutics, Inc. (DMRA) | $1.250B | -6.10 | |
| ArriVent BioPharma, Inc. (AVBP) | United States | $1.485B | -10.25 |
| Innoviva, Inc. (INVA) | United States | $1.493B | 4.62 |